C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/17 (2006.01) A61K 38/22 (2006.01) A61K 38/28 (2006.01) A61K 48/00 (2006.01) A61P 5/48 (2006.01) C12N 15/86 (2006.01)
Patent
CA 2364417
The invention provides methods and compositions for targeting endocrine cells capable of converting an immature expressed protein into a mature protein, and secreting the expressed protein into the systemic circulation. In particular, the invention features methods and compositions for treating disorders, such as diabetes by orally administering a vector expressing insulin to target cells which can subsequently secrete the expressed insulin into the blood circulation.
L'invention concerne des techniques et des compositions permettant de cibler des cellules endocriniennes capables de convertir une protéine immature exprimée en une protéine mature, et de sécréter ladite protéine exprimée dans la circulation systémique. L'invention concerne, en particulier, des techniques et des compositions permettant de traiter des troubles tels que les diabètes par administration orale d'un vecteur exprimant l'insuline vers des cellules cibles, lesquelles cellules peuvent ensuite sécréter l'insuline exprimée dans la circulation sanguine.
During Matthew John
Engene Inc.
Riches Mckenzie & Herbert Llp
LandOfFree
Peroral gene therapy of diabetes and obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peroral gene therapy of diabetes and obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peroral gene therapy of diabetes and obesity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1417734